Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 55, Issue 6, 2012, Pages 679-688

  Samson, Charles M ^a,c   Morgan, Pamela ^a   Williams, Elizabeth ^a   Beck, Lee ^a   Addie Carson, RicJunette ^a   Mcintire, Stacy ^b   Booth, Andrea ^b   Mendez, Eduardo ^b   Luzader, Carolyn ^b   Tomer, Gitit ^a   Saeed, Shehzad ^a   Donovan, Edward ^b   Bucuvalas, John ^b   Denson, Lee A ^a  

^a Division of Gastroenterology Hepatology and Nutrition   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Care guidelines; Chronic illness; Fecal calprotectin; Serum 25 OHD; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; VITAMIN D;

ARTICLE; CHILD; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE REGISTRY; ELECTRONIC MEDICAL RECORD; ENTERITIS; EVIDENCE BASED MEDICINE; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICIAN; POPULATION RESEARCH; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY CONTROL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SELF REPORT; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADOLESCENT; CHILD; COOPERATIVE BEHAVIOR; DELIVERY OF HEALTH CARE; DIETARY SUPPLEMENTS; FEMALE; GUIDELINES AS TOPIC; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STEROIDS; TREATMENT OUTCOME; VITAMIN D;

EID: 84870945662     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318262de16     Document Type: Article

References (50)

1. Kohn LT Corrigan J, Donaldson MS, eds. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press; 2000.
2. National Research Council. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.
3. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45.
4. Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory care delivered to children in the United States. N Engl J Med 2007;357:1515-23.
5. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA 2002;288:1909-14.
6. Schechter MS, Margolis P. Improving subspecialty healthcare: lessons from cystic fibrosis. J Pediatr 2005;147:295-301.
7. Cunningham S, Logan C, Lockerbie L, et al. Effect of an integrated care pathway on acute asthma/wheeze in children attending hospital: cluster randomized trial. J Pediatr 2008;152:315-20.
8. Horbar JD, Carpenter JH, Buzas J, et al. Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial. BMJ 2004;329:1004.
9. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9.
10. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
11. Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol 2004; 99:650-5.
12. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13.
13. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005;100: 1357-61.
14. Colletti RB, Baldassano RN, Milov DE, et al. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2009;49:297-303.
15. Kappelman MD, Bousvaros A, Hyams J, et al. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis 2007;13:890-5.
16. Esrailian E, Spiegel BM, Targownik LE, et al. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther 2007;26:1005-18.
17. Mawdsley JE, Irving PM, Makins RJ, et al. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol 2006; 18:249-53.
18. Tremaine WJ, Sandborn WJ, Loftus EV, et al. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol 2001;96:2401-6.
19. Crandall WKM, Colletti RB, Denson L, et al. Increased remission in a quality-improvement collaborative for pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2009;49:E60.
20. Denson L, Moyer MS, Ballard E, et al. Evidence-based care guidelines-severe inflammatory bowel disease/IBD. http://www.cincinnati childrens.org/assets/0/78/1067/2709/2777/2793/9199/488d3bf6-5f6b-47ca-b263- 9805277ba18b.pdf. Accessed October 26, 2012.
21. Crandall W, Kappelman MD, Colletti RB, et al. ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis 2011;17:450-7.
22. Kappelman MD, Crandall WV, Colletti RB, et al. Short Pediatric Crohn's Disease Activity Index for quality improvement and observational research. Inflam Bowel Dis 2011;17:112-7.
23. Turner D, Otley AR, Mack D, et al. Development and evaluation of a Pediatric Ulcerative Colitis Acitivity Index (PUCAI): a prosepective multicenter study. Gastroenterology 2007;133:433-532.
24. Fagerberg UL, Loof L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:414-20.
25. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24.
26. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
27. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9.
28. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6.
29. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669-73.
30. Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008;103:1451-9.
31. Levin AD, Wadhera V, Leach ST, et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci 2011;56:830-6.
32. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006;118:1950-61.
33. Institute of Medicine/Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press; 2010.
34. Papa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;53:11-25.
35. Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ 2002;325:961-4.
36. Altschuler A, Collins B, Lewis JD, et al. Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis 2008;14:992-9.
37. Margolis PA, Lannon CM, Stuart JM, et al. Practice based education to improve delivery systems for prevention in primary care: randomised trial. BMJ 2004;328:388.
38. Bucuvalas JC, Ryckman FC, Arya G, et al. A novel approach to managing variation: outpatient therapeutic monitoring of calcineurin inhibitor blood levels in liver transplant recipients. J Pediatr 2005; 146:744-50.
39. Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011;56:2372-7.
40. Gerasimidis K, Nikolaou CK, Edwards CA, et al. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011;45:234-9.
41. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010;4:144-52.
42. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
43. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14.
44. El-MataryW, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011;56:825-9.
45. Joseph AJ, George B, Pulimood AB, et al. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure and disease activity. Indian J Med Res 2009;130:133-7.
46. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebocontrolled study. Aliment Pharmacol Ther 2010;32:377-83.
47. Ardizzone S, Cassinotti A, Trabattoni D, et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol 2009;22:63-71.
48. Bartels LE, Jorgensen SP, Agnholt J, et al. 1,25-Dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease. Int Immunopharmacol 2007;7: 1755-64.
49. Crandall WV, Boyle BM, Colletti RB, et al. Development of process and outcome measures for improvement: lessons learned in a quality improvement collaborative for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2011;17:2184-91.
50. Davidoff F, Batalden P, Stevens D, et al. Publication guidelines for quality improvement in health care: evolution of the SQUIRE project. Qual Saf Health Care 2008;17:i3-9.